Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis
Bone mineral density (BMD) reduction and fragility fractures still represent a major source of morbidity in rheumatoid arthritis (RA) patients, despite adequate control of the disease. An increasing number of clinical and experimental evidence supports the role of autoantibodies, especially anti-cit...
Main Authors: | Bernardo D’Onofrio, Michele di Lernia, Ludovico De Stefano, Serena Bugatti, Carlomaurizio Montecucco, Laura Bogliolo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/9/2341 |
Similar Items
-
The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis
by: Ludovico De Stefano, et al.
Published: (2021-11-01) -
The Clinical Value of Autoantibodies in Rheumatoid Arthritis
by: Serena Bugatti, et al.
Published: (2018-12-01) -
Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target
by: Serena Bugatti, et al.
Published: (2021-06-01) -
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
by: Takako Suzuki, et al.
Published: (2017-06-01) -
Novel autoantibodies in rheumatoid arthritis
by: A.F. Bonifacio, et al.
Published: (2019-04-01)